Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31431189 | 0.81 | ADRA1D (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL4362257 | 0.80 | CA1 (0.33) | SMYD2 | |
| SCHEMBL4116949 | 0.78 | SMYD2 (0.31) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL1179211 | 0.75 | CA2 (0.49) | SMN1; SMN2 | |
| SCHEMBL7594780 | 0.72 | KDM4E (0.32) | CYP3A4 | |
| SCHEMBL19475198 | 0.72 | PTGES2 (0.38) | SMYD2 | |
| SCHEMBL31432152 | 0.72 | SMYD2 (0.33) | SMYD2 | |
| SCHEMBL4125423 | 0.72 | ALDH1A1 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL4127473 | 0.72 | — | — | |
| SCHEMBL4127479 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192154-A1 | SULTAM DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192154-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, ADAMTS1 | CYP3A4 2446/4885HTT 451/4885SMN1; SMN2 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.